- Ionis announces positive results from Phase 2 study of ION224, an . . .
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing
- Form 4 for Geary Richard S filed 11 03 2025 - ir. ionispharma. com
The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc any security holder of Ionis Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4
- Ionis Pharmaceuticals to present at upcoming investor conferences
ABOUT IONIS PHARMACEUTICALS, INC As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective
- Form 8-K for Ionis Pharmaceuticals INC filed 07 30 2025
Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing
- Ionis announces GSK has advanced bepirovirsen into Phase 3 development
About Ionis Pharmaceuticals, Inc For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology
- Long-Term Safety of Donidalorsen for the Treatment of Hereditary Angioedema
• Donidalorsen is an investigational drug in late -stage development •Raffi Tachdjianhas received grants or research support from Astria Therapeutics, BioCryst, CSL Behring, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, and Takeda; is a speaker for BioCryst, CSL Behring, Pharming, AstraZeneca, Sanofi-Regeneron Pharmaceuticals
- Ionis to present at upcoming investor conferences | Ionis . . .
Please check www ionispharma com for the latest information A live webcast of the presentations will be available on the Investors Media section of the Ionis website The replays will be available within 48 hours and will be archived for a limited time
- Draft - ir. ionispharma. com
In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries
|